Rapid relief of itch and sleep disturbance observed within 48 hours

The relevant analyses focused on data from the ARCADIA 1 and 2 trials in atopic dermatitis and the OLYMPIA 1 and 2 trials in prurigo nodularis. During those trials, patients reported itch intensity and sleep disturbance daily. Daily assessments of patients with atopic dermatitis and prurigo nodularis using a ≥4-point improvement from baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) and Sleep Disturbance Numerical Rating Scale (SD-NRS) showed that in some patients:


Nemolizumab reduced itch within two days(atopic dermatitis:10.7% nemolizumab-treated compared to 2.9% placebo, 95% CI of the difference: 5.6-10.1; P<0.0001;prurigo nodularis:17.2% nemolizumab-treated compared to 3.7% placebo; 95% CI of the difference: 6.8-16.7; p<0.0001)1

Nemolizumab improved sleep disturbance within two days(atopic dermatitis:9.9% nemolizumab-treated compared to 4.6
=*=*=*=*=*=
当前为第4/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页